Weijie Kong

Peking University — China

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

2h-index13citations5works2.62yr avg

OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(3), Drug Transport and Resistance Mechanisms(3), Tuberculosis Research and Epidemiology(1), Prostate Cancer Treatment and Research(1), Platelet Disorders and Treatments(1)

Publications5 total

Development of PBPK Population Model for End-Stage Renal Disease Patients to Inform OATP1B-, BCRP-, P-gp-, and CYP3A4-Mediated Drug Disposition with Individual Influencing Factors

Pharmaceutics·2025Open Access

Population pharmacokinetic and exposure-response study of a novel anti-tuberculosis drug to inform its dosage design in phase III clinical trial

1 cited

European Journal of Pharmaceutical Sciences·2025· 1 citedOpen Access

Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of <scp>OATP1B</scp> , P‐Gp, <scp>BCRP,</scp> and <scp>CYP3A</scp> in End‐Stage Renal Disease Patients

3 cited

Clinical Pharmacology & Therapeutics·2025· 3 citedOpen Access

Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study

9 cited

Frontiers in Pharmacology·2024· 9 citedOpen Access

Development of the second-generation PBPK model to quantify OATP1B, P-gp, BCRP transporter and CYP3A4 enzyme activity changes for Chinese ESRD patients

2024Open Access

Frequent Co-authors

Dongyang Liu(4), Hao Liang(4), Yujie Wu(3), Song Wang(2), Yue Wang(2), Hao Liang(1), Zhenling Deng(1), Shu Niu(1), Yang Liu(1), Haiyan Li(1), Danxia Zheng(1), Yuejuan Pan(1), Yiyi Hu(1), Zhenbin Jiang(1), Xin-kui Tian(1), Shu‐Hong Bi(1), Feifei Feng(1), Yuyan Jin(1), Jiayu Li(1), Haiyan Li(1)